Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

Showing 1–25 of 51 studies in Disparities in Journal of the American Geriatrics Society (page 1 of 3) · 34,580 in the whole library · How the 0–100 score works

Download bibliography of these 51 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

What “Disparities” covers

Disparities — Differences in dementia risk, diagnosis and care across race, ethnicity, income, geography and sex.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Racial and Ethnic Differences in Knowledge About One's Dementia Status

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Journal of the American Geriatrics Society 2020-04-13

Among subjects identified as having dementia by the prediction model, 43.5% to 50.2%, depending on the survey year, reported that they were informed of the dementia status by their physician. 5 key findings →

Design: cohort study Participants: 8,686 Evidence: moderate

Antipsychotic initiation and use were common during hospitalization, most often for delirium, and individuals were frequently discharged on these medications. 3 key findings →

Design: cohort study Participants: 17,775 Evidence: moderate

High BP accelerates gait slowing in well-functioning older adults over a long period of time, even for those who control their BP or develop hypertension later in life. 4 key findings →

Design: cohort study Participants: 2,733 Evidence: moderate

The analytical sample size of the study was 2,068,937, including 9.9% Black, 82.7% White, and 7.4% Hispanic individuals. 5 key findings →

Design: cohort study Evidence: moderate

Dementia emerged as the most potent risk factor for institutionalization in this 12-year community-based epidemiological study. 3 key findings →

Design: longitudinal study Participants: 1,147 Evidence: moderate

MCI was prevalent in 24.7% of participants at baseline. 2 key findings →

Design: prospective cohort Participants: 3,673 Evidence: moderate

Mini-Mental State exam scores vary with education in blacks and whites

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Journal of the American Geriatrics Society 1991-02-01

Previous studies have suggested that education and race may affect performance on standardized mental status tests. 3 key findings →

Design: longitudinal study Participants: 100 Evidence: moderate

This study demonstrates the acceptability and effectiveness of exercise on neurobehavioral function, even in older people more than 75 years of age. 1 key finding →

Design: randomized controlled trial Participants: 42 Evidence: high

The rate of cognitive change in elderly persons with and without diabetes mellitus is similar, although cognitive performance is poorer in persons with diabetes mellitus. 3 key findings →

Design: cohort study Participants: 1,493 Evidence: moderate

These findings suggest that depressive symptoms precede memory decline, but not vice versa, in late life. 3 key findings →

Design: longitudinal study Participants: 2,425 Evidence: moderate

This analysis combining data from two health systems shows that area deprivation is an independent risk factor for cognitive dysfunction in older adults. 3 key findings →

Design: cross-sectional Participants: 5,186 Evidence: moderate

Attenuation of racial inequalities in older age can be extended to cognitive outcomes, which probably reflects selective survival. 1 key finding →

Design: cross-sectional Participants: 3,875 Evidence: moderate

A registry of the University of Washington Alzheimer's Disease Research Center Satellite. 1 key finding →

Design: cross-sectional Participants: 371 Evidence: low

Black race was associated with greater dementia risk even after adjustment for education and other potential confounders. 4 key findings →

Design: longitudinal study Evidence: moderate

Jump to any of the 3 pages

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomized / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multicenter collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 34,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 34,580 records, built mostly from automated pulls of Europe PMC (68.8% of the library) and OpenAlex (14.7%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,050 records (3% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events

Last updated